Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
ELDN Stock Chart & Stats
$2.13
-$0.17(-3.66%)
At close: 4:00 PM EST
$2.13
-$0.17(-3.66%)
Day’s Range― - ―
52-Week Range$1.35 - $4.68
Previous CloseN/A
Volume121.23K
Average Volume (3M)664.78K
Market Cap
$164.44M
Enterprise Value$125.34M
Total Cash (Recent Filing)$93.40M
Total Debt (Recent Filing)$722.00K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 19, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding75,084,694
10 Day Avg. Volume492,640
30 Day Avg. Volume664,780
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.23
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.42K
Enterprise Value/Ebitda-1.35
Forecast
1Y Price Target
$7.33Price Target Upside244.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financing And Commercial RunwayCompletion of a $57.5 million financing provides resources to continue development of tegoprubart and supports a commercially relevant opportunity given its noninferior efficacy and safety advantages.
Regulatory Pathway And DevelopmentCompany plans to seek regulatory agreement on trial design to advance tegoprubart into a Phase III kidney transplantation study, which could accelerate development if regulators accept the proposed design and data package.
Safety ProfileClinical results reported no biopsy-proven acute rejection or graft loss and indicated fewer opportunistic infections along with lower rates of metabolic, neurologic, and cardiovascular toxicities compared with current standard care, supporting a differentiated safety profile.
Bears Say
Efficacy Versus Standard TherapyFailure to show superiority in estimated glomerular filtration rate versus the established immunosuppressant reduces evidence of clear clinical differentiation on kidney function.
Investor Sentiment And Market ReactionDisappointing efficacy signals combined with limited patient data can weaken investor confidence and increase stock volatility as expectations are reassessed.
Sample Size And Statistical ConfidenceThe small number of patients in the study limits confidence that observed safety and efficacy benefits will hold in a larger, more diverse population.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.68 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $164.44M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 36 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.036.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 75,084,694 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -7.955%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (244.13% Upside)
$7.33 (244.13% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 871.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.68%
12-Months-Change
Fundamentals
Return on Equity
-95.49%
Trailing 12-Months
Asset Growth
13.34%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$7.33
▲(244.13% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
12.00% Insiders
6.15% Mutual Funds
0.04% Other Institutional Investors
74.56% Public Companies and
Individual Investors